NBC News
@NBCNews·11.9M subscribers·98K videos
Ozempic-maker Novo Nordisk struggles as GLP-1 drugs continue to dominate medicine, culture
Posted
March 11, 2026
Views
29,499
Likes
149
Comments
35
Engagement
March 11, 2026
29,499
149
35
0.62%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
See what was published immediately before and after this episode.
3:51Now PlayingThe FDA criticized the maker of Ozempic and Wegovy, Novo Nordisk, for “serious violations” related to the reporting of possible side effects linked to semaglutide, the active ingredient in the drug. NBC News’ Emily Lorsch reports on the GLP-1 drugs.
For more context and news coverage of the most important stories of our day, click here
» Subscribe to NBC News
» Subscribe to Here's the Scoop podcast
Every day, NBC News helps people understand what’s happening and why it matters — through fact-based reporting, meaningful conversations, and powerful stories. From its leading news broadcasts — TODAY, NBC Nightly News, Meet the Press, and Dateline — to NBC News NOW, the 24/7 streaming news channel, plus chart-topping podcasts, the NBC News app, and NBCNews.com, NBC News keeps audiences informed and connected to the stories shaping our world.
Connect with NBC News Online!
NBC News App
Breaking News Alerts
Visit NBCNews.Com
Find NBC News on Facebook
Follow NBC News on Twitter
Follow NBC News on Instagram
#Ozempic #drug #health
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
